Orthofix Medical AI Stock Analysis
Want to see OFIX full AI Analyst Report?
Orthofix Medical (OFIX) AI Stock Analysis
Orthofix Medical
(NASDAQ:OFIX)
OFIX scores low primarily due to weak cash flow (deeply negative TTM free cash flow) and continued net losses despite improving revenue growth and EBITDA margins. Technicals also weigh on the score given the stock’s sharp underperformance versus key moving averages and negative MACD. Earnings-call commentary is mixed—guidance was reduced and 2027 faces an MDR headwind—partially offset by segment strength (Therapeutic Solutions and limb reconstruction) and ongoing profitability improvement.
Orthofix Medical Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down sales across Orthofix’s business lines (such as spinal products, orthopedics, and adjunct therapies), showing which products or segments are driving growth and which are lagging. Understanding the segment mix helps assess diversification, dependency on key product areas, and how new launches or acquisitions could shift future revenue.
Since early‑2023 Global Spine has been the clear growth engine—sales stepped up materially and remain the dominant contributor—while Global Orthopedics, though much smaller, has shown steady acceleration through 2024–25. Management attributes momentum to prioritized distributor relationships, better field execution and upcoming product launches (TrueLok Elevate, Fitbone, VIRATA), which underpin the reaffirmed 2026 guidance. Watch points: lingering biologics softness, timing/stocking variability and modest near‑term EBITDA/cash generation (plus legal settlement risk) could limit upside despite spine strength.
Orthofix Medical (OFIX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $271.87M
- Dividend Yield
- ―
- Average Volume (3M)
- 473.89K
- Price to Earnings (P/E)
- -6.0
- Beta (1Y)
- 0.89
- Revenue Growth
- 2.12%
- EPS Growth
- 63.59%
- Country
- US
- Employees
- 1,605
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Orthofix Medical Business Overview & Revenue Model
Company Description
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Ge...
How the Company Makes Money
Orthofix makes money primarily by selling medical devices and related implants/biologics used in spine and orthopedic procedures and bone-healing therapies. Key revenue streams typically include: (1) Spine hardware and enabling technologies: revenue...
Orthofix Medical Earnings Call Summary
The call presented a mixed outlook. Limb Reconstruction, Therapeutic Solutions, Biologics stabilization, technology launches and improved adjusted EBITDA were positive, but these were offset by below-expectation results, U.S. Spine weakness, supplier and instrument constraints, reduced 2026 guidance, unfavorable mix, cash timing pressure and a stated 2027 MDR revenue headwind.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Orthofix now expects full year 2026 pro forma net sales in the range of $825 million to $830 million and full year 2026 non-GAAP adjusted EBITDA of $86 million to $88 million, with the outlook provided on a non-GAAP pro forma basis, reflecting current foreign currency exchange rates and excluding the discontinued M6 product lines. For the fourth quarter, the company expects sequential growth from normal seasonality and inventory purchases under the European distributor arrangement, with most of the approximately $15 million 2026 net sales benefit expected in the fourth quarter. The European MDR strategy for Spine is expected to create an approximately $22 million net sales headwind in 2027, while MDR requirements are completed. The company is not providing full guidance on 2027, but expects Therapeutic Solutions and limb recon to show above-market growth, core revenue to be in the positive territory backing out the MDR, and Q3, Q4 performance to continue into 2027; core distributors’ growth slowed to the mid-single digits.
Orthofix Medical Financial Statement Overview
Summary
Operational trends are improving (TTM revenue up 26.7%, strong ~69% gross margin, EBITDA margin improved to ~11.5%), but the company remains loss-making (negative operating profit and ~-5.4% net margin). Balance sheet leverage has risen (~0.55x debt/equity) and free cash flow is deeply negative (about -$43.7M TTM), making cash burn and incomplete profitability the key constraints.
Income Statement
46NeutralBalance Sheet
57NeutralCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 835.41M | 822.31M | 799.49M | 746.64M | 460.71M | 464.48M |
| Gross Profit | 577.83M | 551.71M | 545.88M | 486.27M | 337.17M | 349.56M |
| EBITDA | 95.34M | 9.93M | -18.28M | -79.49M | 15.66M | 21.44M |
| Net Income | -45.00M | -92.19M | -126.00M | -151.40M | -19.75M | -38.38M |
Balance Sheet | ||||||
| Total Assets | 855.76M | 850.65M | 893.29M | 925.32M | 458.63M | 476.62M |
| Cash, Cash Equivalents and Short-Term Investments | 86.32M | 82.03M | 83.24M | 33.11M | 50.70M | 87.85M |
| Total Debt | 234.85M | 229.26M | 179.63M | 117.07M | 21.53M | 24.31M |
| Total Liabilities | 426.19M | 400.61M | 390.17M | 326.58M | 121.77M | 139.69M |
| Stockholders Equity | 429.57M | 450.04M | 503.12M | 598.73M | 336.86M | 336.93M |
Cash Flow | ||||||
| Free Cash Flow | -43.67M | -1.28M | -9.09M | -107.80M | -34.70M | -1.12M |
| Operating Cash Flow | 5.01M | 33.35M | 25.79M | -45.75M | -11.54M | 18.48M |
| Investing Cash Flow | -48.53M | -34.60M | -27.58M | -33.13M | -24.53M | -23.01M |
| Financing Cash Flow | 65.73M | -786.00K | 50.71M | 65.32M | -78.00K | -3.62M |
Orthofix Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OFIX, the sentiment is Negative. The current price of 6.67 is below the 20-day moving average (MA) of 8.61, below the 50-day MA of 8.97, and below the 200-day MA of 10.75, indicating a bearish trend. The MACD of -0.71 indicates Positive momentum. The RSI at 29.69 is Positive, neither overbought nor oversold. The STOCH value of 10.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OFIX.
Orthofix Medical Risk Analysis
Orthofix Medical disclosed 54 risk factors in its most recent earnings report. Orthofix Medical reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksOrthofix Medical Peers Comparison
Overall Rating
GMED73Outperform
SIBN70Outperform
BVS66Neutral
ENOV58Neutral
ATEC50Neutral
OFIX44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $9.27B | 16.99 | 11.82% | ― | 13.35% | 32.22% | |
| 70Outperform | $1.04B | -74.61 | -7.57% | ― | 13.99% | 39.54% | |
| 66Neutral | $893.17M | 12.42 | 27.23% | ― | 3.87% | 623.68% | |
| 58Neutral | $1.57B | -2.97 | -35.53% | ― | 3.28% | 62.02% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.08B | -12.34 | -547.17% | ― | 15.34% | 46.31% | |
| 44Neutral | $271.87M | -5.99 | -10.32% | ― | 2.12% | 63.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OFIX | Orthofix Medical Inc. | 6.67 | -7.79 | -53.87% | |
| ATEC | Alphatec | 6.94 | -12.68 | -64.63% | |
| ENOV | Enovis Corporation | 27.22 | 0.05 | 0.18% | |
| GMED | Globus Medical | 69.99 | -13.83 | -16.50% | |
| SIBN | Si-Bone | 23.16 | 4.56 | 24.52% | |
| BVS | Bioventus, Inc. | 10.60 | 3.88 | 57.74% |
Orthofix Medical Corporate Events
Orthofix Reports Third-Quarter Sales Growth and Narrower Loss
PositiveOn November 9, 2026, Orthofix reported third-quarter net sales of $207.9 million, up 1% year over year, while its net loss narrowed to $6.1 million and adjusted EBITDA rose to $26.0 million. Growth in Limb Reconstruction and Therapeutic Solutions off...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
